Abstract
The CML 88 study was designed to evaluate the efficacy of maintenance therapy in a multicentric randomised protocol using IFN combined with low-dose Ara-C versus IFN alone, following an induction with IFN + HU. Between April 1988 and February 1991, 237 patients from 36 French Hematology Centres were entered in the study. Preliminary cytogenetic results show a slightly higher, although not statistically significant, proportion of major chromosomal responses, including complete cytogenetic remissions, in the IFN + Ara C arm.
Publication types
-
Clinical Trial
-
Comparative Study
-
Multicenter Study
-
Randomized Controlled Trial
MeSH terms
-
Adolescent
-
Adult
-
Aged
-
Combined Modality Therapy
-
Cytarabine / therapeutic use*
-
Female
-
France / epidemiology
-
Humans
-
Immunologic Factors / therapeutic use*
-
Interferon alpha-2
-
Interferon-alpha / therapeutic use*
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy*
-
Leukemia, Myeloid, Chronic-Phase / drug therapy
-
Leukemia, Myeloid, Chronic-Phase / therapy*
-
Male
-
Middle Aged
-
Recombinant Proteins
-
Remission Induction
-
Treatment Outcome
Substances
-
Immunologic Factors
-
Interferon alpha-2
-
Interferon-alpha
-
Recombinant Proteins
-
Cytarabine